A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
about
CIViC databaseA systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.Integrated discovery of FOXO1-DNA stabilizers from marine natural products to restore chemosensitivity to anti-EGFR-based therapy for metastatic lung cancer.Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer.Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.Integrated Exploitation of the Structural Diversity Space of Chemotherapy Drugs to Selectively Inhibit HER2 T798M Mutant in Lung Cancer.Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.Conversion of MIG6 peptide from the nonbinder to binder of lung cancer-related EGFR by phosphorylation and cyclization.Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
P2860
Q27612411-0D7970E0-3E73-4A6E-A13D-42BFF8CBD931Q35782291-69DC613B-C87B-4516-9339-586EA5CDDE39Q36137185-AACCF680-837D-442C-9ED0-EEFC39BC249AQ36223164-7EB74B01-7548-40D2-81F8-95BFDD82E147Q41147805-FB8F9B3C-A975-4EEC-880E-6DF1D1F6CA9EQ48922155-523BFED5-F2B5-4078-8AE4-0F137912641EQ49010203-7F59FC1F-3079-4981-A159-F9499DB2A62BQ49017204-6D9FC917-813C-4491-9CDE-E48D584DA7A5Q49136595-7173CB24-149C-41D5-B50B-A9BD2D6E3F81Q50792383-C40CE848-AE1C-4868-9DBF-C52A16950864Q53794752-17F90551-3B03-45D6-91E0-D96CBB97CA9FQ53814708-2278942E-03E9-45A0-9801-027F38AFA3B4
P2860
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A systematic profile of clinic ...... ug resistance and sensitivity.
@ast
A systematic profile of clinic ...... ug resistance and sensitivity.
@en
A systematic profile of clinic ...... ug resistance and sensitivity.
@nl
type
label
A systematic profile of clinic ...... ug resistance and sensitivity.
@ast
A systematic profile of clinic ...... ug resistance and sensitivity.
@en
A systematic profile of clinic ...... ug resistance and sensitivity.
@nl
prefLabel
A systematic profile of clinic ...... ug resistance and sensitivity.
@ast
A systematic profile of clinic ...... ug resistance and sensitivity.
@en
A systematic profile of clinic ...... ug resistance and sensitivity.
@nl
P2093
P2860
P1433
P1476
A systematic profile of clinic ...... ug resistance and sensitivity.
@en
P2093
Haidong Wang
Xinghao Ai
Yingjia Sun
P2860
P2888
P304
P356
10.1007/S00726-014-1716-0
P577
2014-07-01T00:00:00Z
P6179
1004913637